Champigny sur Marne, France

Cèline Steverlynck

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Cèline Steverlynck: Innovator in Skin Disorder Treatments

Introduction

Cèline Steverlynck, an innovative inventor based in Champigny-sur-Marne, France, has made significant contributions to the field of dermatology. With a keen focus on the intersection of inflammation and angiogenesis, Steverlynck's work is gaining traction in the medical community.

Latest Patents

Cèline Steverlynck holds one notable patent for an "Inhibitor of IRS-1 for treating skin disorders." This patent addresses the development of an inhibitor that targets the expression of IRS-1, intended for the treatment of angiogenic and inflammatory skin diseases. Additionally, the invention encompasses a transdermal composition, preferably an ointment, that utilizes this inhibitor for therapeutic purposes.

Career Highlights

Currently, Steverlynck is affiliated with Gene Signal International Sa, a company dedicated to advancing medical treatments and solutions. His patent signifies a pivotal advancement in how skin disorders can be managed, showcasing his expertise and commitment to improving patient care.

Collaborations

During his career, Cèline Steverlynck has worked alongside talented colleagues, including Salman Al-Mahmood and Sylvie Colin. These collaborations highlight the team-oriented approach essential for driving innovation and achieving significant scientific breakthroughs in medical research.

Conclusion

Cèline Steverlynck's contributions to the treatment of skin disorders not only reflect his capabilities as an inventor but also illuminate the importance of collaboration in accelerating healthcare advancements. With his pioneering work, he continues to inspire future developments in dermatological treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…